Research (D) Access to health care

Therapist-guided remote versus in-person cognitive behavioural therapy: a systematic review and meta-analysis of randomized controlled trials

Sara Zandieh MSc MA, Seyedeh Maryam Abdollahzadeh MSc PhD, Behnam Sadeghirad PharmD PhD, Li Wang PhD, Randi E. McCabe PhD, Liam Yao MD PhD, Briar E. Inness MSc, Ananya Pathak MSc, Rachel J. Couban MA MISt, Holly Crandon MBiotech, Kian Torabiardakani BHSc, Peter Bieling PhD, Jason W. Busse DC PhD

Cite as: CMAJ 2024 March 18;196:E327-40. doi: 10.1503/cmaj.230274

Abstract

Background: Cognitive behavioural therapy (CBT) has been shown to be effective for several psychiatric and somatic conditions; however, most randomized controlled trials (RCTs) have administered treatment in person and whether remote delivery is similarly effective remains uncertain. We sought to compare the effectiveness of therapist-guided remote CBT and in-person CBT.

Methods: We systematically searched MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to July 4, 2023, for RCTs that enrolled adults (aged ≥ 18 yr) presenting with any clinical condition and that randomized participants to either therapist-guided remote CBT (e.g., teleconference, videoconference) or in-person CBT. Paired reviewers assessed risk of bias and extracted data independently and in duplicate. We performed random-effects model metaanalyses to pool patient-important primary outcomes across eligible RCTs as standardized mean differences (SMDs). We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance to assess the certainty of evidence and used the Instrument to Assess the Credibility of Effect Modification Analyses (ICEMAN) to rate the credibility of subgroup effects.

Results: We included 54 RCTs that enrolled a total of 5463 patients. Seventeen studies focused on treatment of anxiety and related disorders, 14 on depressive symptoms, 7 on insomnia, 6 on chronic pain or fatigue syndromes, 5 on body image or eating disorders, 3 on tinnitus, 1 on alcohol use disorder, and 1 on mood and anxiety disorders. Moderatecertainty evidence showed little to no difference in the effectiveness of therapistguided remote and in-person CBT on primary outcomes (SMD –0.02, 95% confidence interval –0.12 to 0.07).

Interpretation: Moderate-certainty evidence showed little to no difference in the effectiveness of in-person and therapist-guided remote CBT across a range of mental health and somatic disorders, suggesting potential for the use of therapist-guided remote CBT to facilitate greater access to evidence-based care. **Systematic review registration:** Open Science Framework (https://osf.io/7asrc)

Cognitive behavioural therapy (CBT) is a form of psychotherapy that focuses on the identification and modification of unhelpful thoughts and behaviour patterns and has been shown to be effective for a wide range of mental health and somatic disorders.¹⁻⁵ For example, a 2022 systematic review found moderatecertainty evidence that CBT delivered with physiotherapy probably resulted in large improvements in pain relief and physical functioning for patients with chronic low back pain, compared with physiotherapy alone.⁶ In 2022, more than 5 million Canadians (18.3%) met diagnostic criteria for a mood, anxiety, or substance use disorder,⁷ and 1 in 5 adults live with chronic pain.⁸ In 2019, the World Health Organization advised that access to CBT was essential for evidence-based health care;⁹ however, treatment access is an important barrier to care for people with mental health disorders¹⁰ and those with somatic disorders such as chronic pain.¹¹ Access is particularly an issue in a country as geographically large and sparsely populated as Canada.

In Canada, CBT may be provided within existing governmentfunded health care services (e.g., hospital settings) and by private providers such as registered psychotherapists, social workers, and psychologists, in which case people without private insurance must pay out of pocket. In an effort to increase access, the government of Saskatchewan began providing funding for Internet-based CBT in 2015,¹² as did the Ontario Ministry of Health through the Ontario Structured Psychotherapy Program, starting in 2020;¹³ however, the relative effectiveness of in-person and remote CBT is uncertain.

A previous systematic review addressed this question, searching the literature up to February 2017, and found that Internetbased CBT may be similarly effective to in-person CBT, but suggested that effectiveness could differ by the clinical condition being targeted.¹⁴ A 2019 health technology assessment by Health Quality Ontario found that Internet-delivered CBT was more effective than waitlist control for mild to moderate depression and social anxiety disorder, and may be effective for anxiety and panic disorder, but concluded the relative effectiveness of Internet-delivered CBT and in-person delivery was uncertain.¹⁰ Given that these 2 reviews restricted their searches to Englishlanguage trials, several relevant trials have been published since their literature searches were conducted, and neither review conducted analyses to explore subgroup effects, we sought to compare the effectiveness of therapist-guided remote CBT and inperson CBT by conducting a systematic review and meta-analysis.

Methods

We registered the protocol for our systematic review on the Open Science Framework (https://osf.io/7asrc), adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting checklist,¹⁵ and followed Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance.¹⁶

We made 4 changes to our registered protocol. We increased the sensitivity of our literature search strategy by introducing terms to capture randomized controlled trials (RCTs) that administered CBT via telephone and telehealth. We included the Cochrane Central Register of Controlled Trials (CENTRAL) among the databases that we searched and conducted a subgroup analysis of RCTs that administered CBT on an individual basis versus group therapy. Finally, we conducted a sensitivity analysis by pooling the effect of remote versus in-person CBT for depression in natural units (i.e., original, unaltered units) of the most commonly reported outcome measure among eligible trials.

In our systematic review, we explored the comparative effectiveness of therapist-guided remote and in-person CBT on primary patient-important outcomes among adults presenting with any clinical condition.

Data sources

A medical librarian (R.J.C.) initially developed database-specific search strategies without language restrictions and searched MEDLINE, Embase, PsychInfo, and CINAHL from inception to May 11, 2022. We subsequently expanded our search strategy terms to increase sensitivity, included an additional database (CENTRAL), and re-ran our search of all 5 databases from inception to July 4, 2023 (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.230274/tab-related-content). One of the reviewers (S.Z.) searched the reference lists of all eligible articles and relevant systematic reviews to identify additional studies.

Eligibility criteria and study selection

We included RCTs that enrolled adult patients (aged \geq 18 yr) who were seeking treatment for any clinical condition, randomized to

receive either therapist-guided remote CBT (e.g., teleconference, videoconference) or in-person CBT. We excluded studies that administered CBT without therapist guidance or studies that administered virtual reality treatments in which a therapist accompanied the patient, in person, during treatment. We also excluded RCTs that administered modalities of psychotherapy other than standard CBT (e.g., acceptance and commitment therapy, mindfulness-based CBT, dialectical CBT) or that administered CBT in addition to another psychological intervention (e.g., motivational interviewing).¹⁷

Pairs of reviewers independently screened titles and abstracts of identified citations and full texts of all potentially eligible studies. One author with graduate training in psychology (S.Z.) reviewed all citations and potentially eligible full-text articles, with an independent review by a second reviewer (M.A., B.E.I., L.Y., A.P., K.T., H.C.). The pairs of reviewers resolved discrepancies through discussion to achieve consensus or with involvement of a third reviewer (J.W.B.), if necessary. We used online systematic review software (DistillerSR, Evidence Partners) to facilitate literature screening.

For all full-text articles deemed by a reviewer to be potentially eligible for inclusion, a clinical expert (P.B.), blinded to trial results, assessed the intervention details to confirm eligibility. A second clinical expert (R.E.M.), also blinded to trial results, independently reviewed a subset of full-text articles (43%) where reviewers were uncertain as to eligibility. Agreement between clinical experts on the RCTs they both reviewed for eligibility was perfect.

Data extraction

Each eligible RCT underwent duplicate data abstraction by pairs of trained reviewers (S.Z., M.A., B.E.I., L.Y., A.P., K.T.) working independently and using standardized, pilot-tested forms. Reviewers resolved disagreements through discussion or with the help of a third reviewer (J.W.B.).

We collected information on study characteristics, patient characteristics (as per study report), and treatment details (e.g., number of sessions, compliance rate, therapist background, level of therapist involvement, safety).

We extracted the effect on a patient-important primary outcome for each RCT, which we selected using the following hierarchy.¹⁸ We first looked for the outcome declared as the primary outcome by the trial authors; otherwise, we chose the outcome measure used for sample size calculation or, lastly, we chose the first patient-important outcome reported in the results section of the publication. We defined a patient-important outcome as one for which, if the patient knew that this outcome was the only thing to change with treatment, they would likely elect to receive treatment.¹⁹ We included outcomes reported by patients, but not surrogate outcomes (e.g., changes in blood pressure). When outcome data were available at several time points, we used data from the longest follow-up.

Risk of bias

Six reviewers (S.Z., M.A., B.E.I., L.Y., A.P., K.T.) used the Cochrane risk-of-bias tool for RCTs (RoB 2)²⁰ to assess 5 domains, independently and in triplicate, namely bias arising from the randomization

process, deviations from the intended intervention, missing outcome data, bias in measurement of the outcome, and bias in the selection of the reported results.

Pairs of reviewers (S.Z., M.A., B.E.I., L.Y., A.P., K.T.) explored selective outcome reporting by comparing the reported results with those proposed in the study protocol (if published or publicly available through a clinical trials registry, otherwise by comparing the reported results with those proposed in the study methods). Each trial was designed as having low risk of bias, high risk of bias or some concerns regarding bias.

Statistical analysis

We measured inter-rater agreement of the decision to include an RCT after reviewing the full-text paper using an adjusted κ statistic.²¹ All patient-important primary outcomes across eligible trials were continuous but measured diverse domains with a range of instruments. For each study, we acquired the change from baseline for their primary outcome in each treatment arm. When a change score was not provided, we used mean values at baseline and end of follow-up to calculate the change score. When the standard deviation (SD) for change from baseline was not reported, we used methods described by Weir and colleagues²² and the Cochrane handbook to impute this value.²³

We used the change score and associated SD for therapistguided remote and in-person CBT to calculate the betweengroup standardized mean difference (SMD) using the metan package in Stata.²⁴ We pooled effect estimates using a randomeffects model and the DerSimonian–Laird method²⁵ to derive the pooled SMD and associated 95% confidence interval (95% CI).²³ We used Cohen's *d* thresholds for classifying the magnitude of the SMD as small (0.20), medium (0.50), or large (0.80).²⁶

We pooled the difference in compliance between in-person and remote therapist-guided CBT as the relative risk (RR) and 95% CI using a random-effects model. We rated the compliance thresholds used in RCTs as high (i.e., requiring patient to complete 100% of modules to be considered compliant), moderate (50%–80% of modules completed), or low (< 30% of modules completed).

We performed all statistical analyses using Stata version 17.0 (StataCorp LP). Comparisons were 2-tailed, and we set our level of statistical significance at p of 0.05 or less.

Subgroup analyses and meta-regression

We used visual inspection of forest plots and the *l*² statistic to determine statistical heterogeneity for our pooled effect estimate.²⁷ Following Cochrane guidance, heterogeneity of 0%–40% was considered as perhaps unimportant, 30%–60% as moderate, 50%–90% as substantial, and 75%–100% as considerable.²³ We used meta-regression to establish if a priori factors explained between-study variability for the primary outcome, as long as 2 or more studies were in each subgroup, including clinical condition, whether CBT was provided individually or in group therapy, length of follow-up, and risk of bias.²⁸ Our clinical experts (R.E.M., P.B.) did not anticipate that the delivery format of CBT would show systematic differences in effectiveness based on specific clinical conditions. We also used meta-regression to evaluate the

association between number of treatment sessions and compliance rate by in-person or remote CBT.

We presented all subgroup analyses as forest plots to visualize differences. We assessed the credibility of statistically significant subgroup effects in regression analyses (test of interaction $p \le 0.05$) with the Instrument for Assessing the Credibility of Effect Modification Analyses (ICEMAN).²⁹

Certainty of evidence

Two reviewers (J.W.B., S.Z.) used the GRADE approach to summarize the certainty of evidence for our meta-analysis of primary outcome measures. With GRADE, evidence from RCTs begins as high certainty but may be rated down based on risk of bias, indirectness, imprecision, inconsistency, or small study effects.³⁰ We considered the pooled effect estimate to be precise if the associated 95% CI included only 1 magnitude of effect based on Cohen's *d* thresholds (i.e., large [0.8], medium [0.5], small [0.2], or less than small).²⁶

If we found a credible subgroup effect among RCTs at low, some concern, and high risk of bias, we presented the pooled effect for studies at low risk of bias. If no significant subgroup effect was found, we pooled across all RCTs and did not rate down for risk of bias.²³ We evaluated small-study effects with contour-enhanced funnel plots and the Egger test for continuous outcomes or the Harbord test for dichotomous outcomes.³¹

Sensitivity analysis

We conducted a sensitivity analysis by pooling end-of-study scores for primary outcomes instead of change scores. Post hoc, we pooled treatment effects in natural units among eligible RCTS that enrolled patients with depression to illustrate the comparative effectiveness of in-person versus therapist-guided remote CBT. We selected depression among presenting clinical conditions as this was the most common condition reported among eligible RCTs in which the same outcome measure, the Beck Depression Inventory-II (BDI-II; minimally important difference = 5 points),³² was often reported. We converted other measures of depression to the BDI-II using a validated approach,³³ and pooled between-group change scores across RCTs as the weighted mean difference and 95% CI, and used the DerSimonian–Laird method and a random-effects model.²⁵

Ethics approval

We did not seek ethics approval for this systematic review and meta-analysis of published data.

Results

Of 19115 unique citations, 54 studies were³⁴⁻⁸⁷ eligible for review, including 52 English-language RCTs^{34-79,82-87} and single RCTs published in Mandarin⁸⁰ and Persian,⁸¹ with a total of 5463 participants (Figure 1). Our original search yielded 32 eligible studies, with an additional 22 studies included with the expanded and updated search strategy (Appendix 1). At the full-text review stage, reviewers had almost perfect agreement (κ = 0.81). One RCT assigned participants to 3 arms (12 sessions of in-person CBT, 6 sessions of in-person CBT, and 6 sessions of remote




Figure 1: Flow diagram of study inclusion. Note: CBT = cognitive behavioural therapy.

CBT);⁶³ we included data from the 2 arms with the same number of sessions. Another RCT randomized patients to 3 arms (CBT delivered in-person at the patient's home, in-person CBT at a therapist's office, or remote CBT);⁴⁴ we combined data from both in-person CBT arms for our analysis.

Eligible studies enrolled a median of 80 (interquartile range [IQR] 52–125) patients, 3354 (61.4%) of 5463 participants were female, and among the 52 RCTs that reported age, the median of the average age was 43 (IQR 35–51) years. Trials enrolled patients presenting with anxiety-related disorders (n = 17), depression and mood disorders (n = 14), insomnia (n = 7), chronic pain or fatigue syndromes (n = 6), body image or eating disorders (n = 5), tinnitus (n = 3), mood and anxiety disorders (n = 1), and alcohol use disorder (n = 1) (Table 1).

For delivery of CBT, 19 studies (35%) randomized patients to group therapy, whereas 32 (59%) provided individual therapy; 2 studies (4%) did not specify how CBT was provided and 1 RCT (2%) administered both group and individual therapy. Types of remote CBT included interactive voice response technology,³⁴ computerized CBT,^{39,51,55,58,63} telehealth and telephone-based CBT,^{44,64,65,67,69,71,72,74,76-79,82-85} videoconference,^{57,66,68,73,75,86,87} and Internet-delivered CBT.^{35-38,40-43,45-54,56,59-62,70,80,81}

Involvement of therapists in CBT interventions delivered remotely was variable. For 25 RCTs, remote CBT was delivered in real time by a therapist, requiring a time commitment equivalent to in-person CBT. For the remaining 29 RCTs, therapists supported remote CBT modules that patients completed on their own; when details on time spent by therapists was reported, the

Table 1 (part 1	of 4): Study	characterist	ics					
Study	Country of residence	No. of participants	Mean age, yr	Sex, female, %	Clinical condition	Primary outcome measure	No. of sessions	Length follow-up, d
Alegría, 2014 ⁷⁹	USA Puerto Rico	257	45	82	Depression	Severity of depression measured by Patient Health Questionnaire-9	8	120
Andersson, 2013 ³⁵	Sweden	69	42	78	Depression	Depression severity measured by Montgomery Åsberg Depression Rating Scale	7 for remote, 8 for in- person	1095
Andrews, 2011 ³⁶	Australia	37	32	41	Social phobia	Social phobia measured by Social Interaction Anxiety Scale	6	56
Axelsson, 2020 ³⁷	Sweden	204	39	70	Health anxiety	Health anxiety measured by Health Anxiety Inventory	12	365
Azimi, 2019 ⁸¹	Iran	30	NR	67	Insomnia and comorbid depression	Gross memory impairment measured by Rivermead Behavioural Memory Test	6	30
Bergström, 2010 ³⁸	Sweden	104	34	61	Panic disorder	Panic disorder severity measured by Panic Disorder Severity Scale	10	180
Bessell, 2012 ³⁹	England	56	46	61	Appearance concern	Appearance concern measured by Derriford Appearance Scale-24	8	180
Blom, 2015 ⁴⁰	Sweden	48	54	48	Insomnia	Insomnia severity measured by Insomnia Severity Index	8	180
Burgess, 2012 ⁷⁸	UK	80	37	79	CFS	Fatigue measured by Chalder Fatigue Scale	12 for remote 11 for in- person	365
Carlbring, 2005⁴ ⁶	Sweden	49	35	71	Panic disorder	Anxiety associated with physiologic sensations measured by Body Sensations Questionnaire	7 for remote 9 for in- person	365
Choi, 2014 ⁷⁷	USA	158	65	79	Depression	Depression measured by HAM-D	6	252
Conrad, 2015 ⁴⁷	Germany	84	51	42	Chronic tinnitus	Tinnitus distress measured by Tinnitus Handicap Inventory	18 for remote 10 for in- person	365
de Boer, 2014 ⁴⁸	Netherland	72	52	64	Nonspecific chronic pain	Pain catastrophizing measured by Pain Catastrophizing Scale	8	60

Table 1 (part 2 of 4): Study characteristics

Study	Country of residence	No. of participants	Mean age, yr	Sex, female, %	Clinical condition	Primary outcome measure	No. of sessions	Length follow-up, d
Egede, 2015 ⁷⁶	USA	241	64	2	Depression	Depression measured by BDI	8	360
Frueh, 2007 ⁷⁵	USA	38	56	0	PTSD	PTSD symptom severity measured by PTSD Checklist-M	14	90
Glueckauf, 2012 ⁷⁴	USA	14	67	90	Depression	Depression measured by CES-D	12	91
Gollings, 2006 ⁴⁹	Australia	40	22	100	Body dissatisfaction and disordered eating	Body shape concern measured by Body Shape Questionnaire	8	60
Granberg, 2022 ⁷³	USA	41	33	63	Insomnia	Qualitative measurement examining provider- and patient-level perspectives, attitudes, and preferences regarding CBT-I delivered via telemedicine versus in-person delivery, as well as barriers and facilitators to delivery or receipt of care in each approach	6	90
Hall, 2017 ⁷²	USA	100	49	90	CFS	CFS symptoms measured by Chalder Fatigue Scale	10 for remote 12 for in- person	70 for remote 84 for in- person
Heapy, 2017 ³⁴	USA	125	58	21	Chronic back pain	Pain intensity measured by Numeric Rating Scale	10	270
Hedman, 2011 ⁵⁰	Sweden	126	35	36	Social anxiety disorder	Social phobia measured by Liebowitz Social Anxiety Scale	15	180
Himelhoch, 2013 ⁷¹	USA	34	45	74	Depression	Depression symptom severity measured by HAM-D	11	98
Jarnefelt, 2020 ⁵¹	Finland	53	43	74	Insomnia	Severity of insomnia measured by Insomnia Severity Index	10 for remote 6 for in- person	180
Jasper, 2014 ⁵²	Sweden	84	51	42	Chronic tinnitus	Tinnitus distress measured by Tinnitus Handicap Inventory	18	180
Johansson, 2021 ⁵³	Sweden	301	50	38	Alcohol use disorder	Number of standard drinks consumed measured by timeline follow-back method	8	180
Kaldo, 2008 ⁴³	Sweden	51	46	43	Distress associated with tinnitus	Tinnitus distress measured by Tinnitus Reaction Questionnaire	7	365

Table 1 (part 3 of 4): Study characteristics

Study	Country of residence	No. of participants	Mean age, yr	Sex, female, %	Clinical condition	Primary outcome measure	No. of sessions	Length follow-up, d
Kenardy, 2003 ⁶³	Australia	95	37	76	Panic disorder	Panic–anxiety composite score	6	180
Kheirkhah, 2023 ⁷⁰	Iran	60	33	100	Depression	Depression measured by BDI	9	56
Kiropoulos, 2008 ⁵⁴	Australia	86	39	72	Panic disorder	Panic severity measured by Panic Disorder Severity Scale	12	84
Lancee, 2016 ⁵⁶	Netherland	60	40	80	Insomnia	Insomnia severity measured by Insomnia Severity Index	6	180
Laurel Franklin, 2018 ⁶⁹	USA	18	54	0	Trauma-related insomnia	Sleep problems measured by Pittsburgh Sleep Quality Index	6	90
Leterme, 2020 ⁵⁵	France	80	37	65	Adjustment disorder with anxiety	Trait anxiety measured by State– Trait Anxiety Inventory	5	180
Liu, 2020 ⁶⁸	USA	207	48	23	PTSD	PTSD severity measured by CAPS	12	180
Lovell, 2006 ⁶⁷	UK	72	31	60	OCD	OCD measured by the Yale Brown Obsessive– Compulsive Scale	10	180
Lundström, 2022⁴⁵	Sweden	80	33	65	OCD	OCD severity measured by Yale- Brown Obsessive- Compulsive Scale	10 for remote 16 for in- person	365
Luxton, 2016 ⁶⁴	USA	121	NR	18	Depression	Depression measured by BDI-II	8	90
Maieritsch, 2016 ⁶⁶	USA	90	31	7	PTSD	PTSD severity measured by CAPS	10	84
McAndrew, 2018 ⁸²	USA	128	57	6	Chronic multi- symptom Illness	Role physical measured by Role Physical Subscale VR-36	10	360
Meng, 2019 ⁶⁵	USA	109	59	92	Depressive symptoms	Health services use and total health care expenditures	12	84
Milgrom, 2021 ⁴¹	Australia	78	32	100	Postnatal depression	Severity of depression measured by BDI-II	10 for remote 6 for in- person	147
Mitchell, 2008⁵	USA	128	29	98	Bulimia nervosa	Binge eating frequency measured by Eating Disorder Examination	20	365
Mohr, 2012 ⁸⁴	USA	325	48	78	Depression	Depression measured by HAM-D	18	126
Morland, 2014 ⁸⁷	USA	125	55	0	PTSD	PTSD severity measured by CAPS	12	180
Morland,						Depression measured by HAM-D PTSD severity measured		

Table 1 (part 4 of 4): Study characteristics

Study	Country of residence	No. of participants	Mean age, yr	Sex, female, %	Clinical condition	Primary outcome measure	No. of sessions	Length follow-up, d
Paxton, 2007 ⁶⁰	Australia	79	26	100	Body image and eating disorder	Body dissatisfaction measured by Body Shape Questionnaire	8	180
Peterson, 2022 ⁴⁴	USA	120	41	12	PTSD	PTSD symptom severity measured by PTSD Checklist for DSM-5	12	180
Sadeghijoola, 2022 ⁸³	Iran	40	54	100	Vasomotor symptoms	Frequency of hot flashes measured by Kupperman Hot Flash Index	6	98
Stubbings, 2013 ⁵⁷	Australia	26	30	58	Mood and anxiety disorders	Depression, anxiety, and stress measured by Depression Anxiety and Stress Scale	12	42
Thase, 2018 ⁵⁸	USA	154	46	66	Depression	Depression severity measured by HAM-D	21	180
Vallejo, 2015 ⁶¹	Spain	40	52	100	Fibromyalgia	Global impact of fibromyalgia measured by Fibromyalgia Impact Questionnaire	10	365
Wagner, 2014 ⁵⁹	Switzerland	62	38	65	Depression	Depression severity measured by BDI-II	7	90
Watts, 2020 ⁸⁶	Canada	115	41	83	Generalized anxiety disorder	Working alliance scores measured by Working Alliance Inventory	15	105
Ye, 2016 ⁸⁰	China	53	46	81	Insomnia	Sleep onset latency	8	56
Ying, 2022 ⁴²	China	220	42	53	Depression	Depressive symptoms measured by CES-D	5	180
Zerwas, 2017 ⁶²	USA	196	28	98	Bulimia nervosa	Abstinence from binge eating and purging measured by Eating Disorders Examination Interview	16	365

Note: BDI = Beck Depression Inventory, CAPS = Clinician-Administered PTSD Scale, CBT-I = cognitive behavioural therapy for insomnia, CES-D = Center for Epidemiological Studies Depression Scale, CFS = chronic fatigue syndrome, DSM-5 = *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*, HAM-D = Hamilton Rating Scale for Depression, NR = not reported, OCD = obsessive-compulsive disorder, PTSD = posttraumatic stress disorder, VR-36 = Veterans RAND 36-Item Health Survey.

time commitment typically involved 10–30 minutes per module for responding to patient queries and evaluating submitted homework (Appendix 1, eTable 1).

Treatment duration ranged from 5 to 21 (median 10, IQR 7–12) sessions, and the median length of follow-up was 180 (IQR 90–252) days (Table 1). Among the 44 RCTs that reported patient compliance (Appendix 1, eTable 2), subgroup analysis found no significant difference between in-person or therapist-guided remote CBT; however, effects for moderate- and high-compliance thresholds showed substantial heterogeneity (Figure 2). Meta-regression also found no significant difference in compliance based on the number of treatment sessions for RCTs with high

(p = 0.80), moderate (p = 0.07), or low (p = 0.75) compliance. We found no evidence of small study effects among RCTs reporting patient compliance (Appendix 1, eFigure 1 and eFigure 2).

Safety data were reported by 16 of 54 RCTs (30%) and, of these, 9 (56%) reported no adverse events. Among the 7 RCTs that reported the occurrence of adverse events, 8 serious events were reported, namely suicidal ideation (2 patients, 1 in-person and 1 in remote CBT), hospitalization for a panic attack (1 patient, in-person CBT), victim of domestic violence (1 patient, remote CBT), death after emergency heart surgery (1 patient, in-person CBT), and overdose with acetaminophen (1 patient, remote CBT). One trial reported 2 serious adverse

Study and	patier no. of	ompliant hts/total patients		Woight 06	- Francis		Factoria conta COT
· · ·		in-person	RR (95% CI)	weight, %	Favours in	1-person CBT	
compliance threshold High compliance thresho Carlbring, 2005 ⁴⁶ Kaldo, 2008 ⁴³ Andrews, 2011 ³⁶ Hedman, 2011 ³⁶ Hedman, 2011 ³⁶ Hedman, 2011 ³⁷ Glueckauf, 2012 ⁷⁴ Morland, 2014 ⁴⁷ de Boer, 2014 ⁴⁸ Egede, 2015 ⁷⁶ Vallejo, 2015 ⁶¹ Lancee, 2016 ⁵⁶ Maieritsch, 2016 ⁶⁶ Milgroma, 2021 ⁴¹ Granberg, 2022 ⁴² Kheirkhah, 2023 ⁷⁰ Subgroup, DL ($l^2 = 62.1\%, p = 0.000$) Moderate compliance thr Gollings, 2006 ⁴⁹ Paxton, 2007 ⁸⁰ Kiropoulos, 2008 ⁵⁴ Michell, 2008 ⁵⁵ Bergström, 2010 ³⁸ Mohr, 2012 ⁸⁴ Anderson, 2013 ³⁷ Alegría, 2014 ⁷³ Jasper, 2014 ⁵² Wagner, 2014 ⁵² Wagner, 2014 ⁵² Wagner, 2018 ⁸² Thase, 2018 ⁸² Thase, 2018 ⁸² Thase, 2018 ⁸² Thase, 2018 ⁸² Thase, 2018 ⁸² Thase, 2018 ⁸² Lundstrom, 2022 ⁴⁵ Peterson, 2022 ⁴⁴ Subgroup, DL ($l^2 = 60.0\%, p = 0.000$) Low compliance threshol Mohr, 2012 ⁸⁴ Alegria, 2014 ⁷³ Lundstrom, 2022 ⁴⁵ Peterson, 2022 ⁴⁵ Peterson, 2022 ⁴⁴ Subgroup, DL ($l^2 = 60.0\%, p = 0.242$)	7/25 16(26 14/23 51/64 6/7 46/61 22/38 97/120 20/20 15/30 25/45 52/69 28/39 16/21 83/102 26/30 580/776 esholds (50% 18/21 24/37 41/46 37/62 40/53 129/163 29/33 3/16 12/14 60/87 35/41 25/32 16/24 12/14 60/87 35/41 25/32 16/24 12/14 60/87 35/41 25/32 16/24 12/14 60/87 35/41 25/32 16/24 12/14 60/87 35/41 25/32 16/24 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 60/87 35/61 12/14 80/102 25/43 80/776 12/14 80/102 10/102	In-person 21/24 19/25 14/14 50/62 5/7 50/64 28/34 95/121 20/20 21/30 26/45 53/53 65/79 18/39 15/20 55/85 22/30 5777/752 -80%) 15/19 32/42 38/40 40/66 56/60 109/162 26/36 56/60 109/162 26/36 10/18 11/12 53/84 28/30 20/24 28/30 20/24 28/30 20/24 28/30 20/24 28/30 20/24 31/38 56/76 823/1105 32/162 13/84 46/63 78/98 20/24 38/39 227/470	RR (95% CI) 0.32 (0.17-0.61) 0.63 (0.56-1.18) 0.63 (0.45-0.88) 0.99 (0.83-1.18) 1.20 (0.69-2.10) 0.97 (0.80-1.17) 1.00 (0.91-1.10) 0.71 (0.47-1.10) 0.97 (0.90-1.17) 1.00 (0.91-1.10) 0.92 (0.77-1.08) 1.56 (1.05-2.30) 1.02 (0.77-1.08) 1.56 (1.05-2.30) 1.02 (0.77-1.08) 1.56 (1.05-2.30) 1.02 (0.77-1.48) 1.26 (1.05-1.51) 1.18 (0.91-1.53) 0.97 (0.90-1.05) 1.09 (0.81-1.45) 0.85 (0.64-1.14) 0.94 (0.83-1.06) 0.98 (0.74-1.31) 0.81 (0.68-0.96) 1.18 (1.03-1.34) 1.22 (0.96-1.55) 0.34 (0.11-1.01) 0.94 (0.71-1.23) 1.09 (0.88-1.36) 1.41 (1.07-1.85) 0.84 (0.68-0.96) 1.83 (0.74-1.31) 0.99 (0.88-1.26) 0.34 (0.11-1.01) 0.94 (0.71-1.23) 1.09 (0.88-1.21) 0.84 (0.62-0.99) 1.02 (0.71-1.47) 1.03 (0.88-1.21) 0.84 (0.53-1.33) 1.34 (0.70-2.55) 1.24 (1.04-1.47) 1.12 (0.99-1.16)	Weight, % 1.31 3.27 3.84 8.22 1.70 7.48 4.27 10.14 11.57 2.66 3.46 13.57 8.39 3.06 3.66 7.88 5.50 100.00 3.92 3.90 7.50 4.05 6.41 7.26 4.83 0.45 4.19 5.30 4.20 5.50 3.29 4.88 2.93 6.55 7.64 6.17 6.46 4.59 100.00 2.88 1.51 16.72 2.6.36 7.74 44.78 100.00	Favours in	person CBT	Favours remote CBT
					0.2 0	0.5	1 2 5
						RR (95%	CI)

Figure 2: Effect of patient compliance with remote versus in-person cognitive behavioural therapy (CBT). Weights are from random-effects model; continuity correction applied to studies with 0 cells. Note: CI = confidence interval, DL = DerSimonian–Laird, RR = risk ratio.

events unrelated to study participation without further details. No differences in serious or non-serious adverse events (e.g., increased anxiety) between in-person and therapist-guided remote CBT were observed (Appendix 1, eTable 1).

Risk of bias

Patients and health care providers were unblinded in all RCTs and no study was at high risk of bias for deviation from the intended intervention; however, 5 studies (9%) were at high risk of bias for their randomization process, 10 studies (19%) for missing outcome data, and 9 studies (17%) for measurement of the outcome (e.g., study personnel were aware of intervention received by participants, the participant may have been influenced by knowledge of the intervention for patient-reported

outcomes) (Appendix 1, eTable 4). We found study protocols for 29 (54%) RCTs, (Appendix 1, eTable 5); 5 of 29 were at high risk of bias for selection of their reported results (Appendix 1, eTable 4).

Effect of in-person versus remote CBT on primary outcomes

Moderate-certainty evidence from 51 RCTs (5384 patients) showed little to no difference in effectiveness between in-person and therapist-guided remote CBT on primary outcomes (SMD –0.02, 95% CI –0.11 to 0.07) (Figure 3, Table 2; Appendix 1, eTable 6). We did not find evidence of small-study effects (Appendix 1, eFigure 3). Analysis using end scores also showed little to no difference in effectiveness between in-person and remote CBT (SMD –0.01, 95% CI –0.11 to 0.08) (Appendix 1, eFigure 4).

	Remote CBT		In-per	son CBT					
	No. of		No. of						
Study	participants	$Mean\pmSD$	participants	$Mean\pmSD$	SMD (95% CI)	Weight, %	Favours in-person CBT	Favours remote CBT	
Carlbring, 2005 ⁴⁶	25	16.60 ± 11.60	24	20.70 ± 10.75	-0.37 (-0.93 to 0.20)) 1.67		4	
Gollings, 200649	20	31.20 ± 33.02	19	38.30 ± 41.97	-0.19 (-0.82 to 0.44)) 1.46			
Lovell, 200667	35	11.70 ± 6.83	33	12.20 ± 7.54	-0.07 (-0.55 to 0.41)			— I	
Frueh, 2007 ⁷⁵	17	5.57 ± 12.82	21	1.82 ± 11.59	0.31 (-0.33 to 0.95)	1.42		,−∎ −−	
Paxton, 2007 ⁶⁰ Kaldo, 2008 ⁴³	24 26	39.20 ± 25.23 8.40 ± 16.13	32 25	47.30 ± 28.25 11.40 ± 17.52	-0.30 (-0.83 to 0.23) -0.18 (-0.73 to 0.37)				
(iropoulos, 2008 ⁵⁴	45	4.93 ± 5.30	35	5.56 ± 5.37	-0.12 (-0.56 to 0.32)				
Aitchell, 2008 ⁸⁵	62	7.30 ± 23.39	66	15.30 ± 23.68	-0.34 (-0.69 to 0.01)		L		
Bergström, 2010 ³⁸	43	10.00 ± 4.25	44	9.20 ± 4.78	0.18 (-0.24 to 0.60)	2.29	-	∮∎ —	
ndrews, 2011 ³⁶	14	10.52 ± 14.47	11	12.76 ± 22.11	-0.12 (-0.91 to 0.67)			I	
ledman, 2011 ⁵⁰	64	36.30 ± 22.12	62	31.20 ± 23.31	0.22 (-0.13 to 0.57)	2.67	-		
Bessell, 2012 ³⁹	22 19	12.84 ± 21.68	23 23	14.70 ± 19.42	-0.09 (-0.68 to 0.49)				
Burgess, 2012 ⁷⁸ Glueckauf, 2012 ⁷⁴	6	2.52 ± 3.26 8.00 ± 8.08	5	3.23 ± 3.96 2.80 ± 6.71	-0.19 (-0.80 to 0.42) 0.69 (-0.54-1.92)) 1.52 0.51			
Mohr, 2012 ⁸⁴	163	7.84 ± 6.14	162	10.69 ± 6.10	-0.47 (-0.69 to -0.24		L		
Andersson, 2013 ³⁵	32	14.40 ± 6.66	30	10.60 ± 7.56	0.53 (0.03 to 1.04)	1.89		i I	
Himelhoch, 201371	16	6.30 ± 7.50	18	8.70 ± 6.46	-0.34 (-1.02 to 0.33)	1.32		<u>←</u>	
Stubbings, 2013 ⁵⁷	14	11.83 ± 8.35	11	8.53 ± 8.59	0.39 (-0.41 to 1.19)	1.04			
Alegría, 2014 ⁷⁹	87	2.30 ± 9.23	84	2.98 ± 8.99	-0.07 (-0.37 to 0.23)		1 -	-	
Choi, 201477	49 28	12.46 ± 6.87 13.67 ± 19.38	52 36	13.59 ± 6.64 16.63 ± 20.69	-0.17 (-0.56 to 0.22) -0.15 (-0.64 to 0.35)				
Conrad, 2015 ⁴⁷ asper, 2014 ⁵²	28 41	15.78 ± 29.53	43	10.03 ± 20.09 17.37 ± 20.61	-0.06 (-0.49 to 0.37)				
Iorland, 2014 ⁸⁷	44	15.80 ± 16.56	43	11.20 ± 17.43	0.27 (-0.15 to 0.69)	2.28			
Vagner, 2014 ⁵⁹	17	13.68 ± 6.90	20	8.94 ± 8.61	0.60 (-0.06 to 1.26)	1.36			
le Boer, 201448	22	8.82 ± 12.85	24	4.28 ± 11.47	0.37 (-0.21 to 0.96)	1.61		• • • · · · · · · · · · · · · · · · · ·	
3lom, 2015 ⁴⁰	22	9.40 ± 4.61	23	9.50 ± 4.48	-0.02 (-0.61 to 0.56)				
gede, 2015 ⁷⁶	25 20	14.00 ± 9.97 5.12 ± 17.98	23 20	17.87 ± 10.22 3.29 ± 18.76	-0.38 (-0.96 to 0.19)	1.65 1.49			
/āllejo, 2015 ⁶¹ .ancee, 2016 ⁵⁶	20	5.12 ± 17.98 5.80 ± 4.03	20	9.80 ± 3.31	0.10 (-0.52 to 0.72) -1.10 (-1.72 to -0.48				
uxton, 2016 ⁶⁴	62	12.84 ± 11.86	59	14.71 ± 12.02	-0.16 (-0.51 to 0.20)		l –	<u> </u>	
Maieritsch, 2016 ⁶⁶	45	31.48 ± 19.62	45	30.36 ± 19.06	0.06 (-0.36 to 0.47)	2.33			
′e, 2016 ⁸⁰ (27	46.29 ± 49.32	26	45.39 ± 38.70	0.02 (-0.52 to 0.56)	1.77		— I	
lall, 2017 ⁷²	56	-0.31 ± 4.66	44	2.88 ± 5.63	-0.62 (-1.03 to -0.22			L I	
Heapy, 2017 ³⁴	49	0.51 ± 1.36	45	0.44 ± 1.42	0.05 (-0.35 to 0.46)	2.37			
aurel Franklin, 20 AcAndrew, 2018 ⁸²	18 ⁶⁹ 11 32	3.60 ± 4.76 1.80 ± 12.69	7 32	3.30 ± 4.79 1.10 ± 11.26	0.06 (-0.89 to 1.01) 0.06 (-0.43 to 0.55)	0.80 1.97			
hase, 201858	77	11.90 ± 5.14	77	12.10 ± 5.26	-0.04 (-0.35 to 0.28)				
Azimi, 2019 ⁸¹	15	19.47 ± 4.67	15	19.80 ± 4.25	-0.07 (-0.79 to 0.64)		L	I	
Axelsson, 2020 ³⁷	92	13.20 ± 8.26	90	16.20 ± 7.67	-0.38 (-0.67 to -0.08	3.01			
larnefelt, 2020 ⁵¹	19	2.90 ± 5.06	20	4.30 ± 5.38	-0.27 (-0.90 to 0.36)				
eterme, 2020 ⁵⁵	39	18.10 ± 8.33	38	11.70 ± 10.38	0.68 (0.22 to 1.14)	2.10		i — I	
iu, 2020 ⁶⁸	103 50	14.70 ± 24.88 17.35 ± 19.75	104 65	15.20 ± 23.82 13.56 ± 15.19	-0.02 (-0.29 to 0.25)) 3.13 2.56			
Vatts, 2020 ⁸⁶ ohansson, 2021 ⁵³	150	11.80 ± 12.20	151	13.56 ± 15.19 11.40 ± 11.72	0.22 (-0.15 to 0.59) 0.03 (-0.19 to 0.26)	3.41			
1 ligrom, 2021	39	19.40 ± 7.46	39	12.18 ± 10.35	0.80 (0.34 to 1.26)	2.09		i	
undström, 202245	42	11.77 ± 5.05	38	10.71 ± 4.90	0.21 (-0.23 to 0.65)	2.20		←∎	
eterson, 202244	29	23.70 ± 12.92	50	23.80 ± 15.40	-0.01 (-0.46 to 0.45)			-	
adeghijoola, 2022		13.23 ± 7.81	18	12.60 ± 7.62	0.08 (-0.57 to 0.74)	1.39			
(ing, 2022 ⁴²	110	10.30 ± 3.86	110	9.10 ± 4.07	0.30 (0.04 to 0.57)	3.17	_		
(heïrkhah, 2023 ⁷⁰ Dverall, DL	26 2114	4.96 ± 8.82	22 2133	9.75 ± 10.34	-0.50 (-1.08 to 0.08) -0.02 (-0.12 to 0.07)				
· ·			2135		0.02 (-0.12 (0 0.07)	100.00			
$l^2 = 52.5\%, p < 0.00$	JU1)								
							-2 -1	0 1 2	
							SMD (S	95% CI)	

Figure 3: Effect of remote versus in-person cognitive behavioural therapy (CBT) on primary outcomes. Weights are from random-effects model. Note: CI = confidence interval, DL = DerSimonian–Laird, SD = standard deviation, SMD = standardized mean difference.

We found no credible subgroup effects based on clinical condition, (Appendix 1, eFigure 5 and eTable 3) individual or group therapy (Appendix 1, eFigure 6 and eTable 3), or risk of bias (Appendix 1, eFigures 7–11 and eTable 3). Meta-regression showed no significant association between length of follow-up and the difference in treatment effect between in-person and therapist-guided remote CBT (Appendix 1, eFigures 12–13 and eTable 3).

Three RCTs did not contribute to our meta-analysis because they did not report a patient-important outcome or reported data that were not possible to pool. One evaluated patient and provider perceptions of different forms of CBT for insomnia and found similar satisfaction with telemedicine and in-person delivery.⁷³ The second reported health services use and associated expenditures among caregivers with depressive symptoms who provided care for patients with dementia, and found no difference between in-person and telephone-based CBT.⁶⁵ The third enrolled patients with panic disorder and reported a 3-way repeated-measures analysis of variance that found no difference in outcomes between in-person or therapist-supported, computer-delivered CBT.⁶³

Sensitivity analysis

When restricted to RCTs exploring the effectiveness of in-person and therapist-guided remote CBT for depression, the metaanalysis showed no difference in effect on the 63-point BDI-II (weighted mean difference 0.00, 95% CI –1.75 to 1.75) (Appendix 1, eFigure 14).

Interpretation

Our systematic review found moderate-certainty evidence of little to no difference in effectiveness in CBT delivered either in person Table 2: Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence profile of in-person versus therapist-guided remote cognitive behavioural therapy (CBT) on primary outcomes reported in randomized controlled trials (RCTs) involving patients with psychological and somatic complaints

Outcome	No. of RCTs	No. of participants	Length of follow-up, d median (IQR)	Risk of bias	Inconsistency (I ²)	Indirectness	Imprecision	Small-study effects	SMD (95% CI)	Certainty of evidence
Primary	51	5384	180 (90–252)	Serious*	No serious inconsistency [†] (52%)	No serious indirectness	No serious imprecision	Undetected [‡] Egger <i>p</i> = 0.37	-0.02 (-0.11 to 0.07)	Moderate

Note: CI = confidence interval, IQR = interquartile range, SMD = standardized mean difference.

*All RCTs administered the same intervention in both treatment arms (CBT); however, patients and health care providers were unblinded to the method of delivery (remote or in-person CBT).

†Although the l² value showed moderate heterogeneity, we did not rate down the certainty of evidence because the magnitude and direction of effects were largely consistent across trials, and a substantial proportion of between-study variability was contributed by 1 trial⁵⁶ that contributed less than 2% of the weight to our pooled estimate. ‡A contoured-enhanced funnel plot showed no evidence of small study effects (Appendix 1, eFigure 3), and Egger's test was nonsignificant.

or remotely with therapist support. This finding was unaffected by type of clinical condition, length of follow-up, or whether CBT was provided individually or through group sessions.

Our findings update previous meta-analyses that compared inperson and remote CBT and concluded the need for additional research.^{10,14,88-92} The most recent review included 20 RCTs that compared Internet-delivered CBT with face-to-face CBT and concluded that both appeared similarly effective; however, the authors did not assess the overall certainty of evidence or the credibility of their subgroup analysis based on risk of bias.¹⁴ They suggested that effectiveness may differ based on clinical condition, length of follow-up, and whether CBT was provided individually or in groups.¹⁴ This review restricted the search to English-language RCTs and to a single electronic database, and included 6 RCTs that our experts concluded were not eligible for our review because the remote CBT was not guided by a therapist,^{93,94} the intervention was not conventional CBT,95 the in-person and remote CBT were not similar in content,^{96,97} or the couple therapy intervention that was described as traditional sexual counselling was not comparable to standard individual- or group-delivered CBT.⁹⁸ We addressed the methodologic limitations of this review and identified 40 additional RCTs that had not been included.

To address previous limitations in the evidence, we conducted a comprehensive search for eligible RCTs in any language and engaged clinical experts, blinded to treatment results, to assess the descriptions of all interventions to confirm eligibility. We used the GRADE approach to appraise the certainty of evidence, used predefined subgroup analyses to explore sources of heterogeneity, and assessed the credibility of all potential subgroup effects. Further, although RCTs eligible for our review provided the same intervention administered in person or remotely, we rated down our certainty of evidence for unblinding. This is a conservative approach as several studies have found that most patients are willing to receive psychotherapy in either format,⁹⁹⁻¹⁰¹ and we found no evidence for differential compliance depending on whether CBT was provided in person or remotely, which we would anticipate if patients held strong preferences.

Cognitive behavioural therapy is effective for the treatment of several mental health disorders and somatic complaints;¹⁻⁴ however,

resource requirements are a barrier to in-person therapy. Our review provides moderate-certainty evidence that remote delivery of CBT with therapist guidance is probably similarly effective to inperson delivery. Remote CBT imposes fewer demands on patients' time as travel for face-to-face sessions is unnecessary.¹⁰² Remote CBT may also be more cost-effective than in-person delivery, particularly when the intervention is supported by therapists, rather than being delivered remotely in real time.¹⁰³⁻¹⁰⁵

Our finding that remote CBT is an effective alternative to inperson delivery has potential policy implications. Only 2 Canadian provinces (Saskatchewan and Ontario) currently provide funding for remote CBT.^{12,13} Access to psychotherapy is an important barrier for many people in Canada, particularly those living in remote or rural areas, including military veterans and Indigenous populations, both of which are at high risk for chronic pain and mental health disorders.¹⁰⁶⁻¹⁰⁸

An August 2023 poll of 3189 adults in Canada, commissioned by Mental Health Research Canada, found that the proportion of participants who reported an inability to pay as a reason for not accessing mental health care had increased from 18% to 29% over the previous year.¹⁰⁹ Canada's provinces and territories should consider funding access to therapist-guided remote CBT to facilitate greater access to evidence-based care.

Several options for providing remote psychotherapy are available and use of this delivery method for CBT is likely to evolve rapidly. Recent advances in artificial intelligence tools may open further avenues for providing CBT with reduced involvement of human therapists.¹¹⁰ Future studies should explore whether certain patients have strong preferences for in-person or therapistguided remote CBT, the comparative effectiveness of different types of remote CBT (e.g., high or low involvement of therapist delivering CBT remotely v. in person), and the effectiveness of remote CBT compared with stepped care, whereby remote CBT is provided first, and then non-responders are offered in-person CBT.

Limitations

Although studies eligible for our review involved patients presenting with a wide range of clinical conditions, many conditions that are candidates for CBT were not represented in any studies or in only a single RCT (e.g., alcohol use disorder). Patients enrolled in RCTs eligible for review consented to be randomized to either in-person or remote CBT and likely were not people with strong preferences for 1 method of delivery over the other. Eligible RCTs were conducted in high-income countries, largely enrolled middle-aged participants, and followed patients for a median of 180 days. The generalizability of our findings to lowerincome countries, older patients (who may be less comfortable with technology), and longer follow-up periods is uncertain.

Although we found no important difference in patient compliance between in-person and remote CBT, substantial unexplained heterogeneity was associated with the overall pooled estimate. We did not find evidence for differences in treatment effect based on clinical condition, but the small number of RCTs contributing to some subgroups may have obscured important subgroup effects. Finally, we pooled studies across a variety of outcome measures as the SMD, which limits interpretability and may be affected by baseline heterogeneity of participants.¹¹¹ However, we did pool effects on RCTs of depression to demonstrate results in natural units for this condition and found no difference.

Conclusion

In this systematic review and meta-analysis of RCTs, moderatecertainty evidence found little to no difference in effectiveness between in-person and therapist-guided, remotely delivered CBT for a variety of mental health disorders and somatic conditions. Our findings suggest that therapist-guided remote CBT can be used to facilitate greater access to evidence-based care.

References

- Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. *BMC Psychiatry* 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1.
- Liu J, Gill NS, Teodorczuk A, et al. The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: a meta-analysis of randomized controlled trials. J Affect Disord 2019;245:98-112.
- Williams AC. Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev* 2012;(11):CD007407.
- Busse JW, Montori VM, Krasnik C, et al. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. *Psychother Psychosom* 2009;78:6-15.
- Busse JW, Bhandari M, Guyatt GH, et al. Development and validation of an instrument to predict functional recovery in tibial fracture patients: the Somatic Pre-Occupation and Coping (SPOC). J Orthop Trauma 2012;26:370-8.
- Ho EK-Y, Chen L, Simic M, et al. Psychological interventions for chronic, nonspecific low back pain: systematic review with network meta-analysis. *BMJ* 2022;376:e067718.
- 7. Statistics Canada. Insights on Canadian society: mental disorders and access to mental health care. Cat. no. 75-006-x. 2023. Available: https://www150. statcan.gc.ca/n1/pub/75-006-x/2023001/article/00011-eng.htm (accessed 2024 Feb. 13).
- 8. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. *Pain Res Manag* 2011;16:445-50.
- 9. WHO highlights urgent need to transform mental health and mental health care. Geneva: World Health Organization; updated 2022 June 17. Available: https://www.who.int/news/item/17-06-2022-who-highlights-urgent-need -to-transform-mental-health-and-mental-health-care (accessed 2023 Dec. 24).
- Health Quality Ontario. Internet-delivered cognitive behavioural therapy for major depression and anxiety disorders: a health technology assessment. Ont Health Technol Assess Ser 2019;19:1-199.
- Goldsmith ES, Miller WA, Koffel E, et al. Barriers and facilitators of evidencebased psychotherapies for chronic pain in adults: a systematic review. *J Pain* 2023;24:742-69.

- 12. Saskatchewan mental health innovation highlighted in national podcast [media release]. Regina: Government of Saskatchewan; 2021 Mar. 21. Available: https://www.saskatchewan.ca/government/news-and-media/2021/ march/24/saskatchewan-mental-health-innovation-highlighted-in-national -podcast#:~:text=Since%20its%20inception%20in%202015,million %20into%20the%20ICBT%20program (accessed 2023 Dec. 24).
- 13. Mental health and addictions programs and resources. Toronto: Ontario Health; 2022. Available: https://www.ontariohealth.ca/about-us/our-programs/ clinical-quality-programs/mental-health-addictions/programs-resources (accessed 2023 Dec. 24).
- 14. Carlbring P, Andersson G, Cuijpers P, et al. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. *Cogn Behav Ther* 2018;47:1-18.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6:e1000097.
- Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 2020;119:126-35.
- 17. Hayes SC, Hofmann SG. The third wave of cognitive behavioral therapy and the rise of process-based care. *World Psychiatry* 2017;16:245-6.
- Sun X, Briel M, Busse JW, et al. Subgroup analysis of trials Is rarely easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. *Trials* 2009;10:101. doi: 10.1186/1745-6215-10-101.
- Kersting C, Kneer M, Barzel A. Patient-relevant outcomes: What are we talking about? A scoping review to improve conceptual clarity. *BMC Health Serv Res* 2020;20:596.
- 20. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
- 21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- Weir CJ, Butcher I, Assi V, et al. Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. BMC Med Res Methodol 2018;18:25.
- 23. Higgins JP, Thomas J, Chandler J, et al., editors. *Cochrane handbook for systematic reviews of interventions*. Hoboken (NJ): Wiley-Blackwell/Cochrane Collaboration; 2019.
- 24. Harris RJ, Deeks JJ, Altman DG, et al. Metan: fixed- and random-effects metaanalysis. *Stata J* 2008;8:3-28.
- 25. Murad MH, Montori VM, Ioannidis JPA, et al. Fixed-effects and random-effects models. In: Guyatt G, Rennie D, Meade MO, et al., editors. Users' guides to the medical literature: a manual for evidence-based clinical practice, 3rd ed. New York: McGraw-Hill Education; 2015.
- 26. Cohen J. Statistical power analysis for the behavioral sciences (revised ed.). Hillsdale (NJ): Lawrence Earlbaum Associates; 1988.
- 27. Anzures-Cabrera J, Higgins JPT. Graphical displays for meta-analysis: an overview with suggestions for practice. *Res Synth Methods* 2010;1:66-80.
- Baker WL, Michael White C, Cappelleri JC, et al. Understanding heterogeneity in meta-analysis: the role of meta-regression. *Int J Clin Pract* 2009; 63:1426-34.
- 29. Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020;192:E901-6.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
- Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.
- 32. Hiroe T, Kojima M, Yamamoto I, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. *Psychiatry Res* 2005;135:229-35.
- Thorlund K, Walter SD, Johnston BC, et al. Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. *Res Synth Methods* 2011;2:188-203.
- Heapy AA, Higgins DM, Goulet JL, et al. Interactive voice response-based selfmanagement for chronic back pain: the COPES noninferiority randomized trial. JAMA Intern Med 2017;177:765-73.
- Andersson G, Hesser H, Veilord A, et al. Randomised controlled non-inferiority trial with 3-year follow-up of internet-delivered versus face-to-face group cognitive behavioural therapy for depression. J Affect Disord 2013;151:986-94.
- Andrews G, Davies M, Titov N. Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. *Aust N Z J Psychiatry* 2011;45:337-40.

- Axelsson E, Andersson E, Ljotsson B, et al. Effect of internet vs face-to-face cognitive behavior therapy for health anxiety: a randomized noninferiority clinical trial. JAMA Psychiatry 2020;77:915-24.
- Bergström J, Andersson G, Ljotsson B, et al. Internet-versus groupadministered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. *BMC Psychiatry* 2010;10:54.
- Bessell A, Brough V, Clarke A, et al. Evaluation of the effectiveness of Face IT, a computer-based psychosocial intervention for disfigurement-related distress. *Psychol Health Med* 2012;17:565-77.
- Blom K, Tarkian Tillgren H, Wiklund T, et al. Internet- vs. group-delivered cognitive behavior therapy for insomnia: a randomized controlled non-inferiority trial. *Behav Res Ther* 2015;70:47-55.
- Milgrom J, Danaher BG, Seeley JR, et al. Internet and face-to-face cognitive behavioral therapy for postnatal depression compared with treatment as usual: randomized controlled trial of MumMoodBooster. J Med Internet Res 2021;23:e17185.
- 42. Ying Y, Ji Y, Kong F, et al. Efficacy of an internet-based cognitive behavioral therapy for subthreshold depression among Chinese adults: a randomized controlled trial. *Psychol Med* 2023;53:3932-42.
- Kaldo V, Levin S, Widarsson J, et al. Internet versus group cognitive-behavioral treatment of distress associated with tinnitus: a randomized controlled trial. *Behav Ther* 2008;39:348-59.
- 44. Peterson AL, Mintz J, Moring JC, et al. In-office, in-home, and telehealth cognitive processing therapy for posttraumatic stress disorder in veterans: a randomized clinical trial. *BMC Psychiatry* 2022;41:22.
- Lundström L, Flygare O, Andersson E, et al. Effect of internet-based vs face-toface cognitive behavioral therapy for adults with obsessive-compulsive disorder: a randomized clinical trial. JAMA Network Open 2022;5:e221967-e.
- Carlbring P, Nilsson-Ihrfelt E, Waara J, et al. Treatment of panic disorder: live therapy vs. self-help via the Internet. *Behav Res Ther* 2005;43:1321-33.
- Conrad I, Kleinstauber M, Jasper K, et al. The changeability and predictive value of dysfunctional cognitions in cognitive behavior therapy for chronic tinnitus. *Int J Behav Med* 2015;22:239-50.
- de Boer MJ, Versteegen G, Vermeulen K, et al. A randomized controlled trial of an internet-based cognitive-behavioural intervention for non-specific chronic pain: an effectiveness and cost-effectiveness study. *Eur J Pain* 2014;18:1440-51.
- Gollings EK, Paxton S. Comparison of Internet and face-to-face delivery of a group body image and disordered eating intervention for women: a pilot study. *Eat Disord* 2006;14:1-15.
- Hedman E, Andersson G, Ljotsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. *PLoS One* 2011;6:e18001.
- Jarnefelt H, Harma M, Sallinen M, et al. Cognitive behavioural therapy for insomnia among shift workers: analyses of an RCT study up to 24 months posttreatment. *Int Arch Occup Environ Health* 2020;93:535-50.
- Jasper K, Weise C, Conrad I, et al. Internet-based guided self-help versus group cognitive behavioral therapy for chronic tinnitus: a randomized controlled trial. *Psychother Psychosom* 2014;83:234-46.
- Johansson M, Sinadinovic K, Gajecki M, et al. Internet-based therapy versus face-to-face therapy for alcohol use disorder, a randomized controlled noninferiority trial. *Addiction* 2021;116:1088-100.
- Kiropoulos LA, Klein B, Austin DW, et al. Is Internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT? J Anxiety Disord 2008; 22:1273-84.
- 55. Leterme AC, Behal H, Demarty AL, et al. A blended cognitive behavioral intervention for patients with adjustment disorder with anxiety: a randomized controlled trial. *Internet Interv* 2020;21:100329.
- Lancee J, van Straten A, Morina N, et al. Guided online or face-to-face cognitive behavioral treatment for insomnia: a randomized wait-list controlled trial. *Sleep* 2016;39:183-91.
- 57. Stubbings DR, Rees CS, Roberts LD, et al. Comparing in-person to videoconference-based cognitive behavioral therapy for mood and anxiety disorders: randomized controlled trial. *J Med Internet Res* 2013;15:e258.
- Thase ME, Wright JH, Eells TD, et al. Improving the efficiency of psychotherapy for depression: computer-assisted versus standard CBT. Am J Psychiatry 2018;175:242-50.
- Wagner B, Horn AB, Maercker A. Internet-based versus face-to-face cognitivebehavioral intervention for depression: a randomized controlled non-inferiority trial. J Affect Disord 2014;152-154:113-21.
- Paxton SJ, McLean SA, Gollings EK, et al. Comparison of face-to-face and internet interventions for body image and eating problems in adult women: an RCT. Int J Eat Disord 2007;40:692-704.
- Vallejo MA, Ortega J, Rivera J, et al. Internet versus face-to-face group cognitive-behavioral therapy for fibromyalgia: a randomized control trial. J Psychiatr Res 2015;68:106-13.

- 62. Zerwas SC, Watson HJ, Hofmeier SM, et al. CBT4BN: a randomized controlled trial of online chat and face-to-face group therapy for bulimia nervosa. *Psychother Psychosom* 2017;86:47-53.
- Kenardy JA, Dow MG, Johnston DW, et al. A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial. J Consult Clin Psychol 2003;71:1068-75.
- 64. Luxton DD, Pruitt LD, Wagner A, et al. Home-based telebehavioral health for U.S. military personnel and veterans with depression: a randomized controlled trial. *J Consult Clin Psychol* 2016;84:923-34.
- 65. Meng H, Marino VR, Conner KO, et al. Effects of in-person and telephone-based cognitive behavioral therapies on health services use and expenditures among African-American dementia caregivers with depressive symptoms. *Ethn Health* 2021;26:879-92.
- 66. Maieritsch KP, Smith TL, Hessinger JD, et al. Randomized controlled equivalence trial comparing videoconference and in person delivery of cognitive processing therapy for PTSD. *J Telemed Telecare* 2016;22:238-43.
- Lovell K, Cox D, Haddock G, et al. Telephone administered cognitive behaviour therapy for treatment of obsessive-compulsive disorder: randomised controlled non-inferiority trial. *BMJ* 2006;333:883.
- Liu L, Thorp SR, Moreno L, et al. Videoconferencing psychotherapy for veterans with PTSD: results from a randomized controlled non-inferiority trial. J Telemed Telecare 2020;26:507-19.
- 69. Laurel Franklin C, Walton JL, Raines AM, et al. Pilot study comparing telephone to in-person delivery of cognitive-behavioural therapy for trauma-related insomnia for rural veterans. *J Telemed Telecare* 2018;24:629-35.
- Kheirkhah F, Faramarzi M, Shafierizi S, et al. Preliminary examination of acceptability, feasibility, and effectiveness of internet-based cognitive behavioral therapy for treatment of depression and anxiety in infertile women. *Heliyon* 2023;9:e15760. doi: 10.1016/j.heliyon.2023.e15760.
- Himelhoch S, Medoff D, Maxfield J, et al. Telephone-based cognitive behavioral therapy targeting major depression among urban dwelling, low-income people living with HIV/AIDS: results of a randomized controlled trial. *AIDS Behav* 2013;17:2756-64.
- Hall DL, Lattie EG, Milrad SF, et al. Telephone-administered versus live group cognitive behavioral stress management for adults with CFS. J Psychosom Res 2017;93:41-7.
- 73. Granberg RE, Heyer A, Gehrman PR, et al. Patient and provider experiences with CBT-I administered in-person or via telemedicine: a randomized non-inferiority trial. *Cogent Psychol* 2022;9:2038936.
- Glueckauf RL, Davis WS, Willis F, et al. Telephone-based, cognitive-behavioral therapy for African American dementia caregivers with depression: initial findings. *Rehabil Psychol* 2012;57:124-39.
- 75. Frueh BC, Monnier J, Yim E, et al. A randomized trial of telepsychiatry for posttraumatic stress disorder. *J Telemed Telecare* 2007;13:142-7.
- Egede LE, Acierno R, Knapp RG, et al. Psychotherapy for depression in older veterans via telemedicine: a randomised, open-label, non-inferiority trial. *Lancet Psychiatry* 2015;2:693-701.
- Choi NG, Marti CN, Bruce ML, et al. Six-month postintervention depression and disability outcomes of in-home telehealth problem-solving therapy for depressed, low-income homebound older adults. *Depress Anxiety* 2014;31:653-61.
- Burgess M, Andiappan M, Chalder T. Cognitive behaviour therapy for chronic fatigue syndrome in adults: face to face versus telephone treatment — a randomized controlled trial. *Behav Cogn Psychother* 2012;40:175-91.
- Alegría M, Ludman E, Kafali EN, et al. Effectiveness of the Engagement and Counseling for Latinos (ECLA) intervention in low-income latinos. *Med Care* 2014;52:989-97.
- Ye YY, Liu J, Li XJ, et al. The efficacy of Internet-based cognitive behavioral therapy for insomnia [article in Chinese]. *Med J Chinese People Liberation Army* 2016;41:307-11.
- Azimi M, Moradi A, Hasani J. Effectiveness of cognitive behavioral therapy for insomnia (traditional and Internet-based) on everyday memory of people with insomnia and comorbid depression. *Advance Cognitive Sci* 2019;20:20-34.
- McAndrew LM, Greenberg LM, Ciccone DS, et al. Telephone-based versus inperson delivery of cognitive behavioral treatment for veterans with chronic multisymptom illness: a controlled, randomized trial. *Mil Behav Health* 2018;6:56-65.
- Sadeghijoola N, Afshari P, Jofreh M, et al. Comparing the effects of face-to-face versus phone counseling based on cognitive-behavioral therapy for vasomotor symptoms in postmenopausal women: a randomized controlled trial. *Postep Psychiatr Neurol* 2022;31:114-20.
- Mohr DC, Ho J, Duffecy J, et al. Effect of telephone-administered vs face-toface cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. *JAMA* 2012;307: 2278-85.

- Mitchell JE, Crosby RD, Wonderlich SA, et al. A randomized trial comparing the efficacy of cognitive-behavioral therapy for bulimia nervosa delivered via telemedicine versus face-to-face. *Behav Res Ther* 2008;46:581-92.
- Watts S, Marchand A, Bouchard S, et al. Telepsychotherapy for generalized anxiety disorder: impact on the working alliance. J Psychother Integration 2020;30:208-25.
- Morland LA, Mackintosh MA, Greene CJ, et al. Cognitive processing therapy for posttraumatic stress disorder delivered to rural veterans via telemental health: a randomized noninferiority clinical trial. J Clin Psychiatry 2014;75:470-6.
- Dedert E, McDuffie JR, Swinkels C, et al. Computerized cognitive behavioral therapy for adults with depressive or anxiety disorders. Washington (D.C.): US Department of Veterans Affairs; 2013 Oct. 13.
- Andersson G, Cuijpers P, Carlbring P, et al. Guided Internet-based vs. face-toface cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. *World Psychiatry* 2014;13:288-95.
- Adelman CB, Panza KE, Bartley CA, et al. A meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders. J Clin Psychiatry 2014;75:e695-704.
- Mehta S, Peynenburg VA, Hadjistavropoulos HD. Internet-delivered cognitive behaviour therapy for chronic health conditions: a systematic review and meta-analysis. J Behav Med 2019;42:169-87.
- 92. Luo C, Sanger N, Singhal N, et al. A comparison of electronically delivered and face to face cognitive behavioural therapies in depressive disorders: a systematic review and meta-analysis. *EClinicalMedicine* 2020;24:100442.
- Botella C, Gallego M, Garcia-Palacios A, et al. An Internet-based self-help treatment for fear of public speaking: a controlled trial. *Cyberpsychol Behav Soc Netw* 2010;13:407-21.
- Spek V, Nyklícek I, Smits N, et al. Internet-based cognitive behavioural therapy for subthreshold depression in people over 50 years old: a randomized controlled clinical trial. *Psychol Med* 2007;37:1797-806.
- 95. Lappalainen P, Granlund A, Siltanen S, et al. ACT Internet-based vs face-toface? A randomized controlled trial of two ways to deliver Acceptance and Commitment Therapy for depressive symptoms: an 18-month follow-up. *Behav Res Ther* 2014;61:43-54.
- 96. Andersson G, Waara J, Jonsson U, et al. Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. *Cogn Behav Ther* 2009;38:114-20.
- 97. Andersson G, Waara J, Jonsson U, et al. Internet-based exposure treatment versus one-session exposure treatment of snake phobia: a randomized controlled trial. *Cogn Behav Ther* 2013;42:284-91.
- Schover LR, Canada AL, Yuan Y, et al. A randomized trial of Internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. *Cancer* 2012;118:500-9.

- Renn BN, Hoeft TJ, Lee HS, et al. Preference for in-person psychotherapy versus digital psychotherapy options for depression: survey of adults in the U.S. DNPJ Digit Med 2019;2:6.
- 100. Kozlov E, McDarby M, Prescott M, et al. Assessing the care modality preferences and predictors for digital mental health treatment seekers in a technology-enabled stepped care delivery system: cross-sectional study. JMIR Form Res 2021;5:e30162.
- 101. Alavi N, Moghimi E, Stephenson C, et al. Comparison of online and in-person cognitive behavioral therapy in individuals diagnosed with major depressive disorder: a non-randomized controlled trial. *Front Psychiatry* 2023;14:1113956. doi: 10.3389/fpsyt.2023.1113956.
- 102. Andersson G, Titov N, Dear BF, et al. Internet-delivered psychological treatments: from innovation to implementation. *World Psychiatry* 2019;18:20-8.
- 103. Hedman E, El Alaoui S, Lindefors N, et al. Clinical effectiveness and costeffectiveness of Internet- vs. group-based cognitive behavior therapy for social anxiety disorder: 4-year follow-up of a randomized trial. *Behav Res Ther* 2014;59:20-9.
- 104. Nordgren LB, Hedman E, Etienne J, et al. Effectiveness and cost-effectiveness of individually tailored Internet-delivered cognitive behavior therapy for anxiety disorders in a primary care population: a randomized controlled trial. *Behav Res Ther* 2014;59:1-11.
- 105. Clinically appropriate use of virtual care for depression and anxiety-related conditions: Guidance Reference Document. Toronto: Ontario Health; 2023. Available: https://www.ontariohealth.ca/sites/ontariohealth/files/Depression AnxietyRelatedConditionsVirtualCareGuidance.pdf (accessed 2023 Dec. 24).
- 106. Reyes Velez J, Thompson JM, Sweet J, et al. Cluster analysis of Canadian Armed Forces veterans living with chronic pain: Life After Service Studies 2016. *Can J Pain* 2021;5:81-95.
- 107. Jimenez N, Garroutte E, Kundu A, et al. A review of the experience, epidemiology, and management of pain among American Indian, Alaska Native, and Aboriginal Canadian peoples. *J Pain* 2011;12:511-22.
- 108. Qureshi AR, Patel M, Neumark S, et al. Prevalence of chronic non-cancer pain among military veterans: a systematic review and meta-analysis of observational studies. *BMJ Mil Health* 2023 Dec. 12:e002554. doi: 10.1136/ military-2023-002554. [Epub ahead of print].
- 109. Understanding the mental health of Canadians through COVID-19 and beyond: Poll 17. Toronto: Mental Health Research Canada; 2023. Available: https:// www.mhrc.ca/national-polling (accessed 2023 Dec. 24).
- 110. Eliot L. People are eagerly consulting generative AI ChatGPT for mental health advice, stressing out AI ethics and AI law. Forbes 2023 Jan. 1. Available: https:// www.forbes.com/sites/lanceeliot/2023/01/01/people-are-eagerly-consulting -generative-ai-chatgpt-for-mental-health-advice-stressing-out-ai-ethics-and -ai-law/?sh=75b788592643 (accessed 2023 Dec. 24).
- Cuijpers P. Has the time come to stop using the "standardised mean difference"? Clin Psychol Eur 2021;3:e6835.

Competing interests: Behnam Sadeghirad reports funding from the Canadian Institutes of Health Research, the Michael G. DeGroote Institute for Pain Research and Care, and the Chronic Pain Centre of Excellence for Canadian Veterans. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: Department of Health Research Methods, Evidence, and Impact (Zandieh, Sadeghirad, Wang, Yao, Pathak, Busse), McMaster University, Hamilton, Ont.; Canadian Agency for Drugs and Technology in Health (Zandieh), Toronto, Ont.; Nutrition Research Center, School of Nutrition and Food Sciences (Abdollahzadeh), Shiraz University of Medical Sciences, Shiraz, Iran; Department of Anesthesia (Sadeghirad, Wang, Busse), McMaster University; The Michael G. DeGroote National Pain Centre (Wang, Torabiardakani, Busse), McMaster University; St. Joseph's Healthcare (McCabe, Bieling); Department of Psychiatry and Behavioural Neurosciences (McCabe, Inness, Bieling), McMaster University, Hamilton, Ont.; Institute for Management and Innovation (Crandon), University of Toronto, Mississauga, Ont.

Contributors: Jason Busse conceived and designed the study. Sara Zandieh, Maryam Abdollahzadeh, Liam Yao, Briar Inness, Annaya Pathak, Rachel Couban, Holly Crandon, and Kian Torabiardakani acquired the data. Sara Zandieh and Behnam Sadeghirad carried out the statistical analysis. Sara Zandieh, Behnam Sadeghirad, Li Wang, Randi McCabe, Peter Beiling, and Jason Busse interpreted the data. Sara Zandieh and Jason Busse drafted the manuscript. All of the authors revised the manuscript and contributed important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creative commons.org/licenses/by-nc-nd/4.0/

Funding: Jason Busse is supported, in part, by a Canadian Institutes of Health Research Canada Research Chair in the prevention and management of chronic pain.

Data sharing: The relevant data in this study are available from Sara Zandieh (zandiehs@mcmaster.ca)

Accepted: Jan. 29, 2024

Correspondence to: Jason Busse, bussejw@mcmaster.ca